FDA changes drug approval process amid psychedelics policy debate and survey on psilocybin legalization, plus FDA Breakthrough status for luvesilocin

FDA is moving toward a single “pivotal trial” as the default for drug approvals instead of the historical requirement of two, a shift that could speed market access for psychedelics companies but also raises concerns about whether safety and efficacy evidence will be as robust, especially for psychiatric uses. In parallel, Surgeon General nominee Casey Means faced questions in a Senate hearing about psychedelics after advocating for psilocybin in her 2024 book, with her responses drawing a line between personal support for guided psilocybin therapy and not recommending it as a public health official while the science is still emerging. A RAND survey finds roughly a quarter of US adults support legal use of psilocybin mushrooms, with support differing by substance and increasing interest in supervised medical access. Separately, Reunion Neuroscience received FDA Breakthrough Therapy designation for luvesilocin (a prodrug related to the psilocin analog 4-OH-DiPT) for postpartum depression, with plans for a Phase 3 trial in 2026 aimed at faster regulatory review.